Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN
Clinical Journal of the American Society of Nephrology · 2026
DOI: 10.2215/cjn.0000001077 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Journal of the American Society of Nephrology, 2026. Verfasst von Marina Vivarelli und 15 weiteren Autor:innen. Beteiligte Einrichtung: Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranoproliferative, Complement C3, Complement Inactivating Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Apellis Pharmaceuticals, Swedish Orphan Biovitrum AB, Apellis Pharmaceuticals, Swedish Orphan Biovitrum AB.
Abstract (Originalsprache)
Key Points Adolescents with C3 glomerulopathy/primary immune complex membranoproliferative GN received pegcetacoplan. Proteinuria reduction and stable eGFR in adolescents were consistent with the overall VALIANT population. Pegcetacoplan may resolve pathophysiology underlying C3 glomerulopathy/primary immune complex membranoproliferative GN and prevent long-term kidney damage in a key patient population.
Background
In VALIANT (phase 3; NCT05067127), pegcetacoplan (C3/C3b inhibitor) led to significant proteinuria reduction (>68% versus placebo) and eGFR stabilization in native kidney and posttransplant recurrent C3 glomerulopathy and primary immune complex membranoproliferative GN. Here, we describe results for adolescents (12–17 years) in VALIANT.
Methods
Patients (randomized 1:1) received pegcetacoplan twice weekly or placebo for 26 weeks. For overall population, the primary end point was baseline-to-week 26 change in log-transformed urine protein-to-creatinine ratio (UPCR) in pegcetacoplan versus placebo arms. Key secondary end points were patients achieving composite renal end point (≤15% eGFR reduction and ≥50% UPCR reduction), patients achieving ≥50% UPCR reduction, and eGFR change.
Results
Twenty-eight adolescents received pegcetacoplan; 27 received placebo. Consistent with overall population, pegcetacoplan-treated adolescents achieved clinically meaningful UPCR reduction (relative reduction, 75% [95% confidence interval], 59 to 84; nominal P < 0.001). More adolescents in pegcetacoplan versus placebo arms achieved the composite end point (57% versus 4%; nominal P = 0.002) and ≥50% UPCR reduction (71% versus 4%; nominal P < 0.001). eGFR was stable for pegcetacoplan-treated adolescents (adjusted least squares mean difference [95% confidence interval] versus placebo, +9.7 [−0.026 to 19.382] ml/min per 1.73 m 2 ; nominal P = 0.05). Three adolescents in each group experienced serious treatment-emergent adverse events (pyrexia in one pegcetacoplan-treated patient was considered treatment related). None experienced infection caused by encapsulated bacteria.
Conclusions
Pegcetacoplan induced clinically meaningful proteinuria reduction and eGFR stabilization compared with placebo in adolescents with C3 glomerulopathy or primary immune complex membranoproliferative GN and was well tolerated. Clinical Trial registry name and registration number: ClincialTrials.gov, NCT05067127.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.
- Vall d'Hebron University Hospital, Barcelona, Spain.
- Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
- University of Colorado School of Medicine, Aurora, Colorado.
- Emory School of Medicine, Atlanta, Georgia.
- The Hospital for Sick Children, Toronto, Ontario, Canada.
ORCID-Profile: Marina Vivarelli, Gema Ariceta, Bradley P Dixon, Christoph Licht, Nabil Melhem, Naoya Fujita, Nicole C A J van de Kar, Eli Khankin, Luis López-Lázaro, Carla M Nester
Förderung
- Apellis Pharmaceuticals, Swedish Orphan Biovitrum AB
- Apellis Pharmaceuticals
- Swedish Orphan Biovitrum AB
Zitieren
APA
Vivarelli, M., Ariceta, G., Borovitz, Y., Dixon, B. P., Greenbaum, L. A., Licht, C., Mastrangelo, A., Melhem, N., Fujita, N., van de Kar, N. C. A. J., Wallace, D., Khankin, E., Wang, Z., López-Lázaro, L., Szamosi, J., & Nester, C. M. (2026). Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.0000001077
Vancouver
Vivarelli M, Ariceta G, Borovitz Y, Dixon BP, Greenbaum LA, Licht C, et al. Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN. Clinical Journal of the American Society of Nephrology. 2026. doi:10.2215/cjn.0000001077
BibTeX
@article{Vivarelli2026,
author = {Vivarelli, Marina and Ariceta, Gema and Borovitz, Yael and Dixon, Bradley P and Greenbaum, Larry A and Licht, Christoph and Mastrangelo, Antonio and Melhem, Nabil and Fujita, Naoya and van de Kar, Nicole C A J and Wallace, Dean and Khankin, Eli and Wang, Zhongshen and López-Lázaro, Luis and Szamosi, Johan and Nester, Carla M},
title = {Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2026},
doi = {10.2215/cjn.0000001077}
}
EUVIMED